Executive management team member and leader of legal, quality, regulatory, business development, government affairs and insurance/risk management functions.MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself.

Executive management team member and leader of legal, human resources, government affairs and insurance/risk management functions.

Member of firm with practice focused on:- acting as outside general counsel, primarily to life sciences, medical technology and health care clients- leading internal, third party and government investigations - developing, implementing and assessing compliance and enterprise risk management programs and advising management and boards on legal department structuring and optimization Dykema is a large, national law firm with 13 offices across the United States and the largest law office in San Antonio. The firm is renowned for its litigation practice and serves multinational companies, middle market and family-owned businesses in a variety of industries.

Member of the executive management team with direct reporting and advisory relationship to CEO and Compliance and Audit Committees of Board of Directors. Responsible for leading departments/functions and managing all facets of regulatory, quality and compliance risks. Led organization larger than 350 full-time employees with budget exceeding $35 million. ■ Responsible for governance, risk and compliance, including defending/defining program to shareholders, bond holders, lenders, insurers, external auditors and third party investigators. ■ Leader of numerous anti-corruption, health care compliance and regulatory investigations, domestic and abroad.■ Lead negotiator and key decision-maker in resolution of consolidated multi-plaintiff products liability docket (with more than 350 plaintiffs) and related coverage disputes with products liability insurance carriers; secured favorable resolution with all parties.■ Strategic advisor and member of transaction team leading $2.9 billion sale of regenerative medicine business.■ Leader of quality organization known for successful audit/inspection track record.■ Executive leader called up to secure re-introduction of key product following forced market withdrawal in several EU countries; prevented further market exclusions and secure reversal of forced withdrawal.■ Restructured and rebuilt quality and regulatory teams to better align to enterprise and support substantially enhanced R&D capabilities, and expanded product pipeline; supported more than 40 product launches and secured dozens of new product clearances with FDA, EU-based notified bodies and multiple other jurisdictions/competent authorities.

Executive management team member with direct reporting and advisory relationship to CEO and Compliance and Audit Committees of Board of Directors. Responsible for global compliance and ethics program as well as enterprise risk management. Key assignments included conducting and leading internal investigations as well as interactions with various oversight agencies.■ Developed, launched or enhanced all key compliance programs, including development of global compliance governance model and enhanced anti-corruption and health care compliance programs.■ Strategic advisor and member of transaction team on multiple material transactions, including a more than $400 million acquisition and more than $400 million divesture; responsible for all compliance and risk due diligence efforts as well as integration and/or separation efforts post-closing.■ Developed and launched revised and restructured enterprise risk management program, including establishment of executive management and board oversight model/cadence.■ Lead on multiple material internal investigations on a vast array of legal, compliance and regulatory topics, including matters requiring “shadow investigation” by external auditors and reporting to other oversight agencies.■ Designed and launched new market-entry program to align key stakeholders, properly vet risks versus reward and ensure availability of required resources.

Chief legal officer and member of executive management team for business unit generating about $1.5 billion in global revenue; strategic advisor to Global President and BU executive team. Responsible for all legal and risk matters as well as strategic advice on commercial, R&D, IP and compliance matters. ■ Key negotiator and strategic advisor to board, CEO and President on multiple “bet the business” patent disputes and lawsuits; responsible for establishing resolution and litigation strategies.■ Strategic advisor and “front room” participant in leveraged buyout/“go private” transaction, including lead role on multiple diligence work streams.■ Executive leader and advisor to board’s Special Litigation Committee charged with investigation into allegations of breach of fiduciary duty brought by shareholders related to “go private” transaction; secured dismissal of all suits (no settlement/no payment to plaintiffs).■ Strategic counsel and advisor on key business opportunities, including geographic expansion, business model innovation, in-and-out licensing opportunities and organizational design.■ Strategic business and legal advisor to core team charged with company’s approach to CMS competitive bidding program.■ Responsible for leading multiple internal investigations, including allegations against senior leaders; frequently called upon to develop and execute remediation strategies.

Senior legal professional responsible for global litigation and dispute resolution functions. Areas of responsibility included IP litigation and counseling, product liability litigation and counseling (including multi-district, mass tort and class action lawsuits), labor and employment litigation and counseling, governmental agency actions and investigations, complex commercial litigation, health care compliance investigations and insurance coverage disputes and litigation. ■ Lead attorney and company representative in DOJ-led investigation of company’s government billing practices; secured denial of intervention by government and dismissal of underlying qui tam suits.■ Lead attorney and developer of litigation, trial and appellate strategy in several “bet the business” patent disputes.■ Lead negotiator on multiple material disputes, including class actions, mass torts, IP disputes, contact disputes and insurance coverage disputes.■ Responsible for communicating significant legal, compliance and risk matters to board of directors, investors and analysts, including participation in board meetings, earnings calls and investor presentations.

Litigation shareholder with diverse, complex commercial litigation practice, including lead or first-chair attorney experience on numerous multimillion-dollar disputes. Elected to Equity Shareholder ahead of class and frequently called upon to participate on committees exploring geographic expansion, M&A and other key business initiatives, including hiring, business model innovation and alternative fee arrangements.■ Secured favorable (multimillion-dollar) settlement representing Fortune 500 company in contract and business tort dispute against another Fortune 500 company involving software and related services.■ Secured favorable settlement representing former majority shareholders and sellers in multimillion-dollar fraud and contract suit brought by purchasers of privately held company.■ Secured settlement and bankruptcy court approval of same representing privately held technology company in multimillion-dollar suit brought by trustee of bankrupt entity following the collapse of an anticipated transaction.■ Secured mid-trial settlement in representation of privately held company in multimillion-dollar, multiparty litigation involving significant real estate development transaction.■ Frequent representation of fiduciaries, including law firms and attorneys, officers and directors, financial services companies and advisors and others owing fiduciary duties.